Approval · Notice of Compliance 22261 · 2019
MVASI: Notice of Compliance 22261
Issued June 5, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22261
- Date
- June 5, 2019
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: malignant giloma (who grade iv) - giloblastoma mvasi, in comnination with lomustine is indicated for the treatment of patients with giloblastoma after relapse or disease progression following prior therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MVASI | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 100 MG per 4ML
- BEVACIZUMAB 400 MG per 16ML